Perrigo (NYSE:PRGO) Shares Down 5.7% – Here’s Why

Perrigo Company plc (NYSE:PRGO)’s share price fell 5.7% during trading on Friday . The company traded as low as $10.55 and last traded at $10.52. 996,090 shares were traded during mid-day trading, a decline of 69% from the average session volume of 3,202,232 shares. The stock had previously closed at $11.16.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Perrigo presently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Trading Down 3.9%

The business has a fifty day moving average of $10.66 and a 200-day moving average of $11.92. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The company has a market capitalization of $1.48 billion, a P/E ratio of -0.82, a PEG ratio of 1.27 and a beta of 0.51.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The business had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the business posted $0.60 EPS. Perrigo’s quarterly revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts anticipate that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.8%. The ex-dividend date was Friday, May 29th. Perrigo’s dividend payout ratio is currently -8.85%.

Hedge Funds Weigh In On Perrigo

A number of hedge funds have recently added to or reduced their stakes in the stock. Amundi lifted its holdings in shares of Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Perrigo by 126.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after buying an additional 647,982 shares in the last quarter. United Services Automobile Association bought a new stake in Perrigo during the first quarter worth $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Perrigo by 6.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after buying an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its position in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.